Genomic, phenotypic, and clinical safety of Limosilactobacillus reuteri ATCC PTA 4659.

ABSTRACT: Evaluating the safety of probiotic microorganisms is an important part of the development of probiotic products. In this study, we have performed a systematic safety assessment of Limosilactobacillus reuteri American Type Culture Collection (ATCC) PTA 4659 based on genome analysis, antibiotic susceptibility testing, phenotypic characterization, and a human clinical safety study. Genome sequence analysis showed that the strain is free from virulence and antibiotic resistance genes. Connected to this, phenotypic characterization showed that the strain is susceptible to the main classes of antibiotics. Limosilactobacillus reuteri ATCC PTA 4659 was shown to produce histamine, which has previously been described as an anti-inflammatory mediator produced by certain L. reuteri strains. However, t

SUBMITTER: Sendelius M 

PROVIDER: S-EPMC10689046 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature